Back to News
Market Impact: 0.1
NImmune Biopharma Announces Presentations at ACG 2026 Supporting Efficacy of Oral, Once-Daily NIM-1324 LANCL2 Medicine for Hard-to-Treat IBD
Source: Business Wire
Healthcare & Biotech
NImmune Biopharma announced it will present ACG 2026 data supporting once-daily oral NIM-1324 for patients with co-occurring hard-to-treat inflammatory bowel disease and C. difficile infection. The release provides no clinical efficacy, safety, regulatory, or financial data, limiting its near-term market significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics